• Contact
  • Location
  • Sitemap
  • About
    • Company Profile
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Careers
    • Contact
  • Technology
    • Immunicum’s Approach
    • Ilixadencel
    • Development Programs
    • Publications
  • Pipeline
    • Pipeline
    • Clinical Trial Information
  • Partnering
  • Investors
    • Overview
    • Press releases
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • Subscribe
    • Events & Presentations
    • Corporate Governance
      • Articles of Association
      • General meeting
      • Board of directors
      • Corporate governance reports
      • Senior Executives
      • Nomination Committee
      • Remuneration and the remuneration committee
      • Auditors and audit committee
      • Scientific committee
      • Scientific Advisory Board
    • Shareholder & Stock Info
      • Shareholders
      • Insider
      • Investment calculator
      • Share price look-up
    • Analyst Coverage
    • Financial Reports
    • Financial calendar
    • Secured Rights issue 2018
    • Secured Rights issue 2017
    • Downloads
    • Contacts
  • Investerare (SE)
    • Översikt
    • Pressmeddelanden
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • Prenumerera
    • Events & Presentationer
    • Bolagsstyrning
      • Bolagsordning
      • Bolagsstämma
      • Styrelse
      • Bolagsstyrningsrapporter
      • Ledande befattningshavare
      • Valberedning
      • Ersättningar och ersättningsutskott
      • Revisorer och revisionsutskott
      • Vetenskapligt utskott
      • Vetenskapligt råd
    • Aktien
      • Aktieägare
      • Insiders
      • Investment calculator
      • Share price look-up
    • Analys
    • Finansiella rapporter
    • Finansiell kalender
    • Garanterad nyemission 2018
    • Tidigare emissioner
      • Garanterad nyemission 2017
  • News & Events
    • Press Releases
    • Immunicum in the News
    • Events
Immunicum
  • Contact
  • Location
  • Sitemap
  • About
    • Company Profile
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Careers
    • Contact
  • Technology
    • Immunicum’s Approach
    • Ilixadencel
    • Development Programs
    • Publications
  • Pipeline
    • Pipeline
    • Clinical Trial Information
  • Partnering
  • Investors
    • Overview
    • Press releases
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • Subscribe
    • Events & Presentations
    • Corporate Governance
      • Articles of Association
      • General meeting
      • Board of directors
      • Corporate governance reports
      • Senior Executives
      • Nomination Committee
      • Remuneration and the remuneration committee
      • Auditors and audit committee
      • Scientific committee
      • Scientific Advisory Board
    • Shareholder & Stock Info
      • Shareholders
      • Insider
      • Investment calculator
      • Share price look-up
    • Analyst Coverage
    • Financial Reports
    • Financial calendar
    • Secured Rights issue 2018
    • Secured Rights issue 2017
    • Downloads
    • Contacts
  • Investerare (SE)
    • Översikt
    • Pressmeddelanden
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • Prenumerera
    • Events & Presentationer
    • Bolagsstyrning
      • Bolagsordning
      • Bolagsstämma
      • Styrelse
      • Bolagsstyrningsrapporter
      • Ledande befattningshavare
      • Valberedning
      • Ersättningar och ersättningsutskott
      • Revisorer och revisionsutskott
      • Vetenskapligt utskott
      • Vetenskapligt råd
    • Aktien
      • Aktieägare
      • Insiders
      • Investment calculator
      • Share price look-up
    • Analys
    • Finansiella rapporter
    • Finansiell kalender
    • Garanterad nyemission 2018
    • Tidigare emissioner
      • Garanterad nyemission 2017
  • News & Events
    • Press Releases
    • Immunicum in the News
    • Events
You are here:HomeInvestorsPress ReleasesPressreleases 2014

Investors

  • Overview
  • Press releases
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
    • Subscribe
  • Events & Presentations
  • Corporate Governance
    • Articles of Association
    • General meeting
    • Board of directors
    • Corporate governance reports
    • Senior Executives
    • Nomination Committee
    • Remuneration and the remuneration committee
    • Auditors and audit committee
    • Scientific committee
    • Scientific Advisory Board
  • Shareholder & Stock Info
    • Shareholders
    • Insider
    • Investment calculator
    • Share price look-up
  • Analyst Coverage
  • Financial Reports
  • Financial calendar
  • Secured Rights issue 2018
  • Secured Rights issue 2017
  • Downloads
  • Contacts

Press releases 2014

  • All
  • Regulatory release

Immunicum: Patent application related to Immunicum's therapeutic cancer vaccine SUBCUVAX to be granted in the US

19 December 2014 Read more

Immunicum: The patent application relating to activation of Immunicum's COMBIG-cells for therapeutic cancer vaccination will be granted in the US

15 December 2014 Read more

Immunicum presents safety and survival data from a clinical phase I/II study with INTUVAX in patients with liver cancer

3 December 2014 Read more

Immunicum reports continued promising survival data for INTUVAX-treated renal cancer patients

3 December 2014 Read more

Immunicum's CSO Alex Karlsson-Parra awarded the Athena Prize

26 November 2014 Read more

Immunicum acquires patent for oncolytic therapy and further development of SUBCUVAX

27 October 2014 Read more

Immunicum presents updated survival data for INTUVAX-treated renal cancer patients

12 September 2014 Read more

Immunicum's rights issue oversubscribed

3 June 2014 Read more

Immunicum announces INTUVAX phase I/II data at ASCO 2014

2 June 2014 Read more

Immunicum publishes supplement to prospectus for rights issue

26 May 2014 Read more

Immunicum reports preliminary regression data after add-on therapy with tyrosine kinase inhibitors and continued compelling survival data from the formally completed phase I/II-study in renal cell ...

21 May 2014 Read more

Immunicum - INTUVAX abstract at ASCO 2014

15 May 2014 Read more

Date for Immunicum's interim report for the period July 2013 - March 2014 changed

15 April 2014 Read more

Immunicum has completed a private placement and resolved on a fully underwritten rights issue

2 April 2014 Read more

Immunicum submits the final report for its phase I/II trial in metastatic renal cell carcinoma showing positive safety data and promising survival data

31 March 2014 Read more

Immunicum's abstract with data from a kidney cancer study has been approved for presentation at the 2014 ASCO Annual Meeting in Chicago

27 March 2014 Read more

Immunicum reports promising preclinical results for its CD70 technology in adoptive immunotherapy

6 March 2014 Read more

Immunicum: Interim Report July - December 2013

18 February 2014 Read more
Press releases

Choose which language you would like to receive the press release in:

Swedish English
Contact us
Stockholm

Östermalmstorg 5
114 42 Stockholm
Sweden

Telephone

+46 31 41 50 52

Email

info@immunicum.com

For information about personal data processing at Immunicum, please see Immunicum´s Integrity Policy

Social
Links
  • Sitemap
  • Integrity and Cookie Policy

© 2002-2019 Immunicum AB. All rights reserved.

Designer mkmedia
To top

We use cookies to improve the user experience on Immunicum. Read more about Cookies

Approve